Shlaes D M
Infectious Diseases Section, Cleveland Department of Veterans Affairs Medical Center, Ohio.
Clin Ther. 1993;15 Suppl A:21-8.
An 18-month prospective study of Enterobacter bacteremia was conducted in 129 patients. The results indicated that (1) emergence of resistance was more frequent during treatment with third-generation cephalosporins than with other antibiotics; (2) the addition of an aminoglycoside to the cephalosporin did not prevent emergence of resistance; (3) previous treatment with cephalosporins was associated with bacteremia caused by multiresistant Enterobacter species; and (4) infection with multiresistant Enterobacter species was associated with a higher mortality than infection with susceptible strains. It is concluded that avoidance of third-generation cephalosporins for surgical prophylaxis and therapy in patients in whom Enterobacter infections are suspected or proven should lower the prevalence of Enterobacter bacteremias and mortality and prevent the emergence of multiresistance.
对129例患者进行了为期18个月的肠杆菌菌血症前瞻性研究。结果表明:(1)与使用其他抗生素相比,第三代头孢菌素治疗期间耐药性出现更为频繁;(2)在头孢菌素中添加氨基糖苷类药物并不能预防耐药性的出现;(3)既往使用头孢菌素治疗与多重耐药肠杆菌属细菌引起的菌血症有关;(4)多重耐药肠杆菌属细菌感染比敏感菌株感染的死亡率更高。得出结论,对于怀疑或已证实有肠杆菌感染的患者,在手术预防和治疗中避免使用第三代头孢菌素应可降低肠杆菌菌血症的发生率和死亡率,并防止多重耐药性的出现。